Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Changi General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT04775329
- Locations
- 🇸🇬
Wong Yu Jun, Singapore, Singapore
Microbial Resistance of Rifaximin in Hepatic Encephalopathy
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-02-03
- Target Recruit Count
- 100
- Registration Number
- NCT04736836
Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bayhealth Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04674176
- Locations
- 🇺🇸
Bayhealth Medical Center- Dover Family Physicians and GI Consultants Office, Dover, Delaware, United States
Efficacy and Safety of Rifaximin With NAC in IBS-D
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT04557215
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- AB Biotics, SA
- Target Recruit Count
- 8
- Registration Number
- NCT04316806
- Locations
- 🇪🇸
Dr. Bofill Clinic, Girona, Spain
Multi-dimensional Clinical and Pathophysiological Profiles of Patients With Functional Dyspepsia and Effect of Gut Microbiota Manipulation Using Rifaximin for Its Treatment
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2020-03-10
- Target Recruit Count
- 132
- Registration Number
- NCT04302402
- Locations
- 🇮🇳
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India
🇮🇳Department of Critical Care Medicine, SGPGIMS, Lucknow, UP, India
Rifaximin in Patients With Diabetic Gastroparesis
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT04254549
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
- Conditions
- Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2 Positive Breast CarcinomaPrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT04249622
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- MetroHealth Medical Center
- Registration Number
- NCT04244877
Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT04161053
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.